Miller Andrew D
Institute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, Waterloo Campus, 150 Stamford Street, London SE1 9NH, UK ; GlobalAcorn Ltd., London, UK.
J Drug Deliv. 2013;2013:165981. doi: 10.1155/2013/165981. Epub 2013 Jul 9.
Today, researchers are constantly developing new nanomaterials, nanodevices, and nanoparticles to meet unmet needs in the delivery of therapeutic agents and imaging agents for cancer therapy and diagnosis, respectively. Of particular interest here are lipid-based nanoparticles (LNPs) that are genuine particles (approximately 100 nm in dimension) assembled from varieties of lipid and other chemical components that act collectively to overcome biological barriers (biobarriers), in order for LNPs to preferentially accumulate in or around disease-target cells for the functional delivery of therapeutic agents for treatment or of imaging agents for diagnosis. The capabilities of these LNPs will clearly vary depending on functional requirements, but the nanoscale allows for an impressive level of diversity in capabilities to enable corresponding LNPs to address an equally diverse range of functional requirements. Accordingly, LNPs should be considered appropriate vehicles to provide an integrated, personalized approach to cancer diagnosis and therapy in future cancer disease management.
如今,研究人员不断开发新的纳米材料、纳米器件和纳米颗粒,以分别满足癌症治疗和诊断中治疗剂和成像剂递送方面尚未满足的需求。这里特别令人感兴趣的是基于脂质的纳米颗粒(LNPs),它们是由多种脂质和其他化学成分组装而成的真正颗粒(尺寸约为100纳米),这些成分共同作用以克服生物屏障,使LNPs能够优先在疾病靶细胞内或其周围积累,以便功能性递送治疗剂进行治疗或递送成像剂进行诊断。这些LNPs的能力显然会因功能要求而异,但纳米尺度允许在能力方面有令人印象深刻的多样性,使相应的LNPs能够满足同样多样化的功能要求。因此,在未来的癌症疾病管理中,LNPs应被视为提供综合、个性化癌症诊断和治疗方法的合适载体。